High treatment-related mortality in cardiac amyloid patients undergoing autologous stem cell transplant

[1]  R. Tsang,et al.  Intensification of the stem cell transplant induction regimen results in increased treatment-related mortality without improved outcome in multiple myeloma , 1999, Bone Marrow Transplantation.

[2]  R. Bataille,et al.  Prognostic factors for survival and response after high‐dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients , 1998, British journal of haematology.

[3]  R. Falk,et al.  Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients. , 1998, Blood.

[4]  M. Jadoul,et al.  Allogeneic bone marrow transplantation for AL amyloidosis , 1997, Bone Marrow Transplantation.

[5]  T. Therneau,et al.  A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. , 1997, The New England journal of medicine.

[6]  R. Falk,et al.  Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: one-year follow-up in five patients. , 1996, Blood.

[7]  R. Bataille,et al.  High-dose melphalan and autologous bone marrow transplantation for systemic AL amyloidosis with cardiac involvement. , 1996, Blood.

[8]  R. Falk,et al.  Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only. , 1996, The American journal of medicine.

[9]  J. Mehta,et al.  Marrow transplantation in multiple myeloma. , 1992, New England Journal of Medicine.

[10]  R. Kyle,et al.  Response rates and survival in primary systemic amyloidosis. , 1991, Blood.

[11]  R. Kyle,et al.  Primary systemic amyloidosis: clinical and laboratory features in 474 cases. , 1995, Seminars in hematology.